OR-AIRSHIP
16.5.2019 15:02:09 CEST | Business Wire | Press release
Customer engagement company Airship today announced May and June dates and locations for its 2019 Customer Engagement Forum , a year-long global event series. These interactive sessions feature leaders from many of the world's leading brands discussing their plans and practices for customer engagement (CX) in a digital world — arming marketers with proven strategies, research and techniques to connect with customers in smarter, faster, and more effective ways.
Dubbed ELEVATE, the educational series will kick-off in Santa Monica on May 21, 2019 and San Francisco on May 30, 2019. In June, the forum series will come to Paris , Chicago , New York , Amsterdam and London . Seats are limited; those interested in attending should reserve their spot using the city-specific links above. Additional cities and dates will be announced later this year.
Featuring a unique collection of speakers in each city, the series will focus on the growing focus on customer experience (CX) as the key driver of many companies’ growth and competitive strategies. Among topics such as CX best practices and innovation, the program will also include a discussion of building a business case for the value of better customer experience (CX).
According to Gartner, “Today, slightly more than two-thirds of marketers responsible for CX say their companies compete on the basis of CX. In two years, this expectation rises even further, with 81% of respondents anticipating their companies will do so.” (Gartner, Customer Experience in Marketing Survey 2017: Greater Expectations, Greater Challenges, Augie Ray, Jane-Anne Mennella, Simon Yates, Refreshed April 9, 2019, Published 5 October 2017).
Customer Engagement Forum attendees will gain a sharper understanding of what’s at stake when it comes to getting customer engagement right — learning about the CX trends experts are watching, as well as the CX tech stack and common team structures. Beyond a notebook full of ideas to leapfrog the competition and crush their KPIs, attendees will gain stats to build a business case for the value of better CX to grow their budgets and their careers.
“Forrester analyzed the correlation between CX quality and revenue growth for companies in five industries ... companies with superior CX grew revenues five times faster on average than their competitors with inferior CX. And this is a global phenomenon” (Forrester Research, Inc., “Improving CX Through Business Discipline Drives Growth,” June 19, 2017; Updated March 26, 2018).
Companies speaking at Customer Engagement Forum events include AccuWeather, AMC Theatres, Expensify, Footlocker, France TV, GSN Games, Tribune Publishing, Turner Sports and Zillow, with more to come.
“Today’s fastest-growing brands separate themselves from the pack by providing unique experiences that deliver surprising convenience and delight to their customers,” said Mike Stone, SVP of Marketing, Airship. “The Airship Customer Engagement Forum provides marketers an incredible opportunity to learn successful CX strategies from leading brands, as well as the programs and tactics to put them into place.”
For more information on Airship’s Customer Engagement Forum 2019, or to register, please visit forum.airship.com .
About Airship
Marketing and digital experience teams at thousands of the world’s most admired companies rely on Airship’s Customer Engagement Platform to create deeper connections with customers by delivering incredibly relevant, orchestrated messages on any channel.
Founded in 2009 as a pioneer in push notifications, Airship now gives brands the user-level data, engagement channels, AI orchestration and services they need to deliver push notifications, emails, SMS, in-app messages, mobile wallet cards and more to exactly the right person in exactly the right moment — building trust, boosting engagement, driving action and growing value.
Learn more about our Customer Engagement Platform , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005238/en/
Contact:
North America: Dave Struzzi Bateman Group +1 415-697-2560 airship@bateman-group.com
Corey Gault Airship +1 503-206-9164 corey@airship.com
EMEA: Nicolas Vitre Airship +33 1 44 56 88 21 +33 6 88 04 76 86 nicolas.vitre@airship.com
UK: Lucinda Layton Hotwire UK +44 20 7608 2500 Airship@hotwireglobal.com
France: Marion Fajgenbaum / Marine Cressot Hotwire France +33 14 312 55 68 / 69 AirshipFR@hotwireglobal.com
Germany: Julia da Silva Bastos Hotwire Germany +49 89 2620 81 89 airshipde@hotwireglobal.com
Spain: Beatriz Pérez Hotwire Spain +34 917 44 1265 beatriz.perez@hotwireglobal.com
Italy: Sara Tetti Hotwire Italy +39 349 5788052 AirshipIT@hotwireglobal.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom